Evidence map›Paper›PMID 41329742›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Erasable serum markers.

Shirin Nouraein, Honghao Li, Sangsin Lee, Vidal A Saenz, Emma K Raisley, Sho Watanabe, Vincent D Costa, Jerzy O Szablowski

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Shirin NouraeinDepartment of Bioengineering, Rice University, Houston, TX 77005.ORCID 0000-0003-3423-1002
Honghao LiDepartment of Bioengineering, Rice University, Houston, TX 77005.ORCID 0009-0003-5545-4755
Sangsin LeeDepartment of Bioengineering, Rice University, Houston, TX 77005.
Vidal A SaenzDepartment of Bioengineering, Rice University, Houston, TX 77005.
Emma K RaisleyDepartment of Bioengineering, Rice University, Houston, TX 77005.ORCID 0009-0001-0794-5168
Sho WatanabeDepartment of Bioengineering, Rice University, Houston, TX 77005.ORCID 0000-0002-3277-097X
Vincent D CostaDepartment of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA 30043.ORCID 0000-0002-5412-8945
Jerzy O SzablowskiDepartment of Bioengineering, Rice University, Houston, TX 77005.ORCID 0000-0001-7851-5408

Funding

Monitoring neuronal activity with a blood test - Released Markers of Activity (RMA)DP2EB035905 · NIBIB · RICE UNIVERSITY · PI Jerzy Olgierd Szablowski · 2023 to 2026
$2.3M
HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB) DP2EB035905NIBIB NIH HHS DP2 EB035905NSF | NSF Graduate Research Fellowship Program (GRFP) 1842494
6 · The paper itself

Abstract

Gene expression in the brain is typically evaluated using invasive biopsy or postmortem histology. Serum markers provide an alternative way to monitor the brain, but relatively few such markers exist. Additionally, the origin of serum markers often cannot be localized to a specific cell population, and monitoring dynamic changes in their gene expression is compromised by the same factor that makes the markers detectable-long serum half-life. Here, we propose a paradigm to improve the sensitivity of serum marker measurement by modifying them with an external chemical stimulus. As a proof of concept, we use a well-controlled system with known half-life and tunable serum levels. This system, released markers of activity (RMA), or RMAs enables measurement of transgene expression in the brain through a simple blood test. RMAs are stable in blood, with a half-life of >100 h and can detect expression from as few as 12 neurons in mice. However, their long serum half-life also generates detectable background signals when RMA are used to track temporal changes in gene expression. By engineering on-demand erasable RMAs and injecting an intravenous targeted protease, we reduced RMA background signal by more than an order of magnitude without compromising the detection sensitivity. Similarly to previous RMA iterations, our approach showed a 65,000-fold increase in their signal over the baseline when expressed in a single brain region but also improved the dynamic range of detection for low-level promoter activity that is driven by physiological levels of c-Fos.

Indexed as

BiomarkersBrainAnimalsHalf-LifeHumansMiceNeuronsTransgenesBiomarkersgene expression monitoringserum markertemporal resolution

Identifiers

PMID41329742
PMCPMC12704721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.